Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267233 | 0.87 | MAPT (0.42) | ALKBH2HPGDSEGLN1NPC1MAPT | |
| SCHEMBL5269393 | 0.83 | TSHR (0.47) | L3MBTL1TSHRNPC1MAPTRAB9A | |
| SCHEMBL27985786 | 0.83 | BAZ2B (0.42) | ALKBH2HPGDSEGLN1NPC1MAPT | |
| SCHEMBL27745237 | 0.78 | TDP1 (0.53) | ALKBH1L3MBTL1NPC1MAPTHTT | |
| SCHEMBL5267207 | 0.78 | MLYCD (0.44) | ALKBH2HPGDSEGLN1ALKBH1NPC1 | |
| SCHEMBL7254281 | 0.77 | GAA (0.48) | ALKBH2HPGDS | |
| SCHEMBL8313319 | 0.77 | KCNN4 (0.36) | — | |
| SCHEMBL1195324 | 0.76 | AKR1B1 (0.44) | TSHRNAPRTMAPTHTTRAB9A | |
| SCHEMBL20772213 | 0.75 | MAPT (0.36) | ALKBH2HPGDSNPC1MAPTRAB9A | |
| SCHEMBL15012958 | 0.74 | RECQL (0.46) | TSHRNPC1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| CN-1158610-A | Quinoxaline derivatives useful in therapy | PFIZER LTD (IE) | 1997-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | ALKBH2 4750/4885HPGDS 31/4885EGLN1 397/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | ALKBH2 4725/4885HPGDS 1105/4885EGLN1 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.